APF530

DRUG2 trials

Sponsors

Heron Therapeutics

Conditions

Chemotherapy-induced Nausea and VomitingNausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific

Phase 3

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

CompletedNCT00343460

Heron TherapeuticsNausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2006-06-01End: 2009-02-01Updated: 2026-03-02

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

CompletedNCT02106494

Heron TherapeuticsChemotherapy-induced Nausea and Vomiting

Start: 2014-03-01End: 2015-05-01Updated: 2026-03-02

Related Papers

Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.

Journal of Clinical Oncology2016-05-203 citations

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.

Journal of Clinical Oncology2016-05-201 citations

APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

Future Oncology2016-03-2122 citations

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

BMC Cancer2016-02-267 citations

Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial

Cancer Research2016-02-152 citations

Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

Journal of Clinical Oncology2015-10-01

Slow-Release Granisetron (APF530) Versus Palonosetron for Chemotherapy-Induced Nausea/Vomiting: Analysis by American Society of Clinical Oncology Emetogenicity Criteria

Future Oncology2015-08-2014 citations

A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?

Journal of Clinical Oncology2014-05-202 citations

Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.

Journal of Clinical Oncology2014-05-202 citations